This website uses cookies so that we can provide you with the best user experience possible. Our Cookie Notice is part of our Privacy Policy and explains in detail how and why we use cookies. To take full advantage of our website, we recommend that you click on “Accept All”. You can change these settings at any time via the button "Update Cookie Preferences" in our Cookie Notice.
Technical cookies are required for the site to function properly, to be legally compliant and secure. Session cookies only last for the duration of your visit and are deleted from your device when you close your internet browser. Persistent cookies, however, remain and continue functioning on repeat visits.
CMS does not use any cookie based Analytics or tracking on our websites; see details here.
Personalisation cookies collect information about your website browsing habits and offer you a personalised user experience based on past visits, your location or browser settings. They also allow you to log in to personalised areas and to access third party tools that may be embedded in our website. Some functionality will not work if you don’t accept these cookies.
Gene editing enables targeted alteration of DNA in the genome, essentially allowing the genetic makeup of a living organism to be customised. Gene editing techniques involve the use of engineered nucleases, including zinc-finger nucleases, TALENs and the CRISPR/Cas system. These approaches can be used for research, diagnostic and eventually therapeutic purposes.
All gene editing techniques bring challenges, for example, off-target activity and complexity of use, but in recent years the use of the CRISPR/Cas system in particular has gained momentum. The CRISPR/Cas system is a highly customizable tool that is constantly evolving, with the new prime editing approach hitting the patent headlines in 2019.
Due to the fast-paced and contentious nature of this field, gene editing inventions can present complex scenarios from a patent perspective. These require careful consideration of filing strategies, particular attention to enablement of the invention, or issues relating to multi-party oppositions. Our patent attorneys are highly experienced both in dealing with these technologies and the specific challenges they raise, having worked with various gene editing companies, in particular CRISPR technology companies, finding innovative solutions to get the best possible outcome for our clients.
Social Media cookies collect information about you sharing information from our website via social media tools, or analytics to understand your browsing between social media tools or our Social Media campaigns and our own websites. We do this to optimise the mix of channels to provide you with our content. Details concerning the tools in use are in our privacy policy.